1
|
Pein F, Pinkerton R, Berthaud P, Pritchard-Jones K, Dick G, Vassal G. Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours. Eur J Cancer 2007; 43:2074-81. [PMID: 17716890 DOI: 10.1016/j.ejca.2007.07.003] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2006] [Revised: 06/25/2007] [Accepted: 07/04/2007] [Indexed: 10/22/2022]
Abstract
PSC 833 is an effective MDR1 reversal agent in vitro, including studies with paediatric cancer cell lines such as neuroblastoma and rhabdomyosarcoma. This study was performed to determine the safety profile, dose limiting toxicity (DLT) and maximum tolerated dose (MTD) in children with solid tumours and to determine the influence of PSC 833 on the pharmacokinetics of co-administered etoposide. Each patient received one cycle of intravenous etoposide (100 mg/m2 daily for 3 days on three consecutive weeks) to document baseline pharmacokinetics, and subsequently the same schedule using a dose of 50 mg/m2 was given combined with PSC 833 given orally every 6h at a starting dose of 4 mg/kg. Thirty two eligible patients (23 male, median age 8.3 years) were enrolled. Neuroblastoma and rhabdomyosarcoma were the common disease types. Brain tumours were excluded. DLT was defined as any non-haematological grade 3-4 toxicity (common toxicity criteria) and using a specific toxicity scale for cerebellar toxicity. The MDT was defined as the first dose below which 2 or more patients per dose level experienced DLT. Grade 1-2 ataxia occurred in cohorts 2 and 3 (4 and 5 mg/kg, respectively). Three patients developed grade 3 neurotoxicity in the 6 mg/kg cohort and this defined the MTD. Six responses were observed (2 CR, 4 PR). Pharmacokinetic studies indicated that the clearance of etoposide was reduced by approximately 50% when combined with PSC 833. It is concluded that the toxicity profile and MDT is similar in both children and adults, as is the effect on etoposide metabolism. The study demonstrated the feasibility and safety of carrying out a paediatric phase 1 trial across European boundaries and acts as a model for future cooperative studies in rare cancers among children.
Collapse
Affiliation(s)
- F Pein
- Institut Regional du Cancer Nantes Atlantique, Dept de Recherche Therapeutique, CLCC Rene Gauducheau, Nantes, France
| | | | | | | | | | | |
Collapse
|
2
|
Morland B, Geoerger B, Le Deley MC, Doz F, Pichon F, Frappaz D, Gentet JC, Landman-Parker J, Berthaud P, Vassal G. 246 INVITED Imatinib mesylate in recurrent solid tumours expressing KIT or PDGFR (phase II). EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)70251-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
3
|
Delannoy A, Delabesse E, Lhéritier V, Castaigne S, Rigal-Huguet F, Raffoux E, Garban F, Legrand O, Bologna S, Dubruille V, Turlure P, Reman O, Delain M, Isnard F, Coso D, Raby P, Buzyn A, Caillères S, Darre S, Fohrer C, Sonet A, Bilhou-Nabera C, Béné MC, Dombret H, Berthaud P, Thomas X. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 2006; 20:1526-32. [PMID: 16838024 DOI: 10.1038/sj.leu.2404320] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Acute lymphoblastic leukemia (ALL) in the elderly is characterized by its ominous prognosis. On the other hand, imatinib has demonstrated remarkable, although transient, activity in relapsed and refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL), which prompted us to assess the use of imatinib in previously untreated elderly patients. ALL patients aged 55 years or older were given steroids during 1 week. Ph+ve cases were then offered a chemotherapy-based induction followed by a consolidation phase with imatinib and steroids during 2 months. Patients in complete response (CR) after consolidation were given 10 maintenance blocks of alternating chemotherapy, including two additional 2-month blocks of imatinib. Thirty patients were included in this study and are compared with 21 historical controls. Out of 29 assessable patients, 21 (72%, confidence interval (CI): 53-87%) were in CR after induction chemotherapy vs 6/21 (29%, CI: 11-52%) in controls (P=0.003). Five additional CRs were obtained after salvage with imatinib and four after salvage with additional chemotherapy in the control group. Overall survival (OS) is 66% at 1 year vs 43% in the control group (P=0.005). The 1-year relapse-free survival is 58 vs 11% (P=0.0003). The use of imatinib in elderly patients with Ph+ ALL is very likely to improve outcome, including OS.
Collapse
Affiliation(s)
- A Delannoy
- Department of Hematology, Hôpital de Jolimont, Haine-Saint-Paul, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Maloisel F, Dubruille V, Varet B, Escoffre-Barbe M, Berthaud P, Meresse V, Mahon F, Preudhomme C, Guilhot J, Guilhot F. Design and first interim analysis of a randomized phase III trial comparing imatinib versus imatinib (IM) based combination therapies in newly diagnosed chronic myelogenous leukemia patients in chronic phase. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.6589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6589 Background: Despite impressive results achieved with IM 400 mg/day alone, only a minority of pts reached a complete molecular remission at 12-month. Higher dose of IM or its combination with other therapies might improve molecular remission. Design of the trial: the 3 experimental arms are IM 400mg daily in combination with Peg-IFN-α2a (Peg-IFNα2a, 90 μg weekly) or with Ara-C (20 mg/m2/day, days 15–28 of 28-day cycles) or IM 600mg daily. The reference arm is IM 400mg daily. All pts (over 18 years of age with Bcr-Abl positive CML) receive IM 400 mg/day as monotherapy days 1–14 and then start the assigned regimen for at least 12 months. The endpoints are overall survival (primary), rate and duration of hematologic, cytogenetic and molecular responses and tolerability. An interim analysis of the first 636 pts at 1 year from randomization will allow evaluation of molecular response rates, one of the experimental arm being selected for further comparison with IM 400. An experimental arm would be selected if it increased the 4 log reduction response rate at 12-month by at least 20 percentage points, (15% to 35%), with an acceptable tolerability. Results: This evaluation is based on a cohort of 370 pts with a median time of observation of 16 months, recruited between 9/2003 and 9/2005. [median age 53 yrs (18–81); Sokal distribution: 38% of pts low, 38% intermediate, and 24% high]. At 1 month 80% of pts achieved complete hematologic response. At 12 months, 138 pts (72%) achieved a major cytogenetic response, being complete in 120 pts (63%). Grade 3/4 hematologic toxicity occurred in 8% of IM400 pts, 9% of IM600 pts, 41% of IM+IFN pts and 33% of IM+Ara-c pts respectively. Dose of Peg IFN was reduced in 16% of pts, 45 μg per week being well tolerated. Grade 3/4 non hematological toxicity occurred in 11% of IM400 pts, 16% of IM600 pts, 10% of IM+IFN pts (maily skin rash) and 11% of IM+Ara-c pts. Discontinuation of experimental treatment occurred in 17% of IM600 pts, 36% of IM+IFN pts and 16% of IM+Ara-c pts. Conclusion: This first analysis confirmed both feasibility of IM combinations and high response rates. However a substantial hematological toxicity requires a careful assessment of pts. [Table: see text]
Collapse
Affiliation(s)
- F. Maloisel
- Fi-Lmc; Department of Hematology, Strasbourg, France; Department of Hematology, Nantes, France; Department of Hematology, Paris, France; Department of Hematology, Rennes, France; Novartis Pharma France, Rueil-Malmaison, France; Roche Pharma, Paris, France; Laboratory of Hematology, Bordeaux, France; Laboratory of Hematology, Lille, France; Clinical Research Centre, Poitiers, France; Department of Hematology, Poitiers, France
| | - V. Dubruille
- Fi-Lmc; Department of Hematology, Strasbourg, France; Department of Hematology, Nantes, France; Department of Hematology, Paris, France; Department of Hematology, Rennes, France; Novartis Pharma France, Rueil-Malmaison, France; Roche Pharma, Paris, France; Laboratory of Hematology, Bordeaux, France; Laboratory of Hematology, Lille, France; Clinical Research Centre, Poitiers, France; Department of Hematology, Poitiers, France
| | - B. Varet
- Fi-Lmc; Department of Hematology, Strasbourg, France; Department of Hematology, Nantes, France; Department of Hematology, Paris, France; Department of Hematology, Rennes, France; Novartis Pharma France, Rueil-Malmaison, France; Roche Pharma, Paris, France; Laboratory of Hematology, Bordeaux, France; Laboratory of Hematology, Lille, France; Clinical Research Centre, Poitiers, France; Department of Hematology, Poitiers, France
| | - M. Escoffre-Barbe
- Fi-Lmc; Department of Hematology, Strasbourg, France; Department of Hematology, Nantes, France; Department of Hematology, Paris, France; Department of Hematology, Rennes, France; Novartis Pharma France, Rueil-Malmaison, France; Roche Pharma, Paris, France; Laboratory of Hematology, Bordeaux, France; Laboratory of Hematology, Lille, France; Clinical Research Centre, Poitiers, France; Department of Hematology, Poitiers, France
| | - P. Berthaud
- Fi-Lmc; Department of Hematology, Strasbourg, France; Department of Hematology, Nantes, France; Department of Hematology, Paris, France; Department of Hematology, Rennes, France; Novartis Pharma France, Rueil-Malmaison, France; Roche Pharma, Paris, France; Laboratory of Hematology, Bordeaux, France; Laboratory of Hematology, Lille, France; Clinical Research Centre, Poitiers, France; Department of Hematology, Poitiers, France
| | - V. Meresse
- Fi-Lmc; Department of Hematology, Strasbourg, France; Department of Hematology, Nantes, France; Department of Hematology, Paris, France; Department of Hematology, Rennes, France; Novartis Pharma France, Rueil-Malmaison, France; Roche Pharma, Paris, France; Laboratory of Hematology, Bordeaux, France; Laboratory of Hematology, Lille, France; Clinical Research Centre, Poitiers, France; Department of Hematology, Poitiers, France
| | - F. Mahon
- Fi-Lmc; Department of Hematology, Strasbourg, France; Department of Hematology, Nantes, France; Department of Hematology, Paris, France; Department of Hematology, Rennes, France; Novartis Pharma France, Rueil-Malmaison, France; Roche Pharma, Paris, France; Laboratory of Hematology, Bordeaux, France; Laboratory of Hematology, Lille, France; Clinical Research Centre, Poitiers, France; Department of Hematology, Poitiers, France
| | - C. Preudhomme
- Fi-Lmc; Department of Hematology, Strasbourg, France; Department of Hematology, Nantes, France; Department of Hematology, Paris, France; Department of Hematology, Rennes, France; Novartis Pharma France, Rueil-Malmaison, France; Roche Pharma, Paris, France; Laboratory of Hematology, Bordeaux, France; Laboratory of Hematology, Lille, France; Clinical Research Centre, Poitiers, France; Department of Hematology, Poitiers, France
| | - J. Guilhot
- Fi-Lmc; Department of Hematology, Strasbourg, France; Department of Hematology, Nantes, France; Department of Hematology, Paris, France; Department of Hematology, Rennes, France; Novartis Pharma France, Rueil-Malmaison, France; Roche Pharma, Paris, France; Laboratory of Hematology, Bordeaux, France; Laboratory of Hematology, Lille, France; Clinical Research Centre, Poitiers, France; Department of Hematology, Poitiers, France
| | - F. Guilhot
- Fi-Lmc; Department of Hematology, Strasbourg, France; Department of Hematology, Nantes, France; Department of Hematology, Paris, France; Department of Hematology, Rennes, France; Novartis Pharma France, Rueil-Malmaison, France; Roche Pharma, Paris, France; Laboratory of Hematology, Bordeaux, France; Laboratory of Hematology, Lille, France; Clinical Research Centre, Poitiers, France; Department of Hematology, Poitiers, France
| |
Collapse
|
5
|
Bui BN, Le Cesne A, Ray-Coquard I, Duffaud F, Rios M, Adenis A, Bonpas E, Perol D, Berthaud P, Blay J. Do patients with initially resected metastatic GIST benefit from ‘adjuvant‘ imatinib (IM) treatment? Results of the prospective BFR14 French Sarcoma Group randomized phase III trial. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.9501] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9501 Background: Metastatic GIST patients (pts) without residual disease after surgical resection are considered as at very high risk of relapse (VHR) but the impact of imatinib (IM) treatment while in CR (‘adjuvant‘ IM) is still debated. Preliminary data for such patients included in the modified BFR14 (continuation vs discontinuation of IM after 3 years of treatment) are presented. Methods: Characteristics and outcome of patients with VHR at inclusion and treated with IM were analyzed. Pts initially allocated to the discontinuation of BFR14 after 1 year of IM were excluded from this analysis. Results: Out of 265 pts with advanced disease, 96 metastatic, completely resected, GIST pts (52 males and 44 females) were included in the trial with a median age of 61 years (range 28 to 87). Primary resected sites were gastric and small bowel in 40% and 42% of cases respectively. Site of dissemination in synchronously resected (R0/R1 resections) metastases was liver only (45%), peritoneum only (15%) and liver plus peritoneum (22%). The median duration of ‘adjuvant‘ IM in the whole population of 96 pts was 13 months (range 0 to 34.3). At time of analysis (december 2005), 34 pts have progressed and 13 pts died of their disease. The median PFS was 25 months (CI 95%: 20.3 ; 34.4) and the 2 year-OS was 80.7% (CI 95%: 68.6 ; 92.8). Conclusions: These results confirm the poor prognosis of VHR GIST pts and justify IM treatment of initially resected metastatic GIST like other metastatic diseases. Optimal duration of IM has to be validated in a prospective way and these pts are considered in BFR 14 trial Updated results will be presented at the meeting. This work is supported by research funding from Novartis Pharma. [Table: see text]
Collapse
Affiliation(s)
- B. N. Bui
- Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre Leon Berard, Lyon, France; Hôpital La Timone, Marseille, France; Centre Alexis Vautrin, Nancy, France; Centre Oscar Lambret, Lille, France; Centre René Gauducheau, Nantes, France; Novartis, Rueil-Malmaison, France; Hôpital Edouard Herriot, Lyon, France
| | - A. Le Cesne
- Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre Leon Berard, Lyon, France; Hôpital La Timone, Marseille, France; Centre Alexis Vautrin, Nancy, France; Centre Oscar Lambret, Lille, France; Centre René Gauducheau, Nantes, France; Novartis, Rueil-Malmaison, France; Hôpital Edouard Herriot, Lyon, France
| | - I. Ray-Coquard
- Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre Leon Berard, Lyon, France; Hôpital La Timone, Marseille, France; Centre Alexis Vautrin, Nancy, France; Centre Oscar Lambret, Lille, France; Centre René Gauducheau, Nantes, France; Novartis, Rueil-Malmaison, France; Hôpital Edouard Herriot, Lyon, France
| | - F. Duffaud
- Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre Leon Berard, Lyon, France; Hôpital La Timone, Marseille, France; Centre Alexis Vautrin, Nancy, France; Centre Oscar Lambret, Lille, France; Centre René Gauducheau, Nantes, France; Novartis, Rueil-Malmaison, France; Hôpital Edouard Herriot, Lyon, France
| | - M. Rios
- Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre Leon Berard, Lyon, France; Hôpital La Timone, Marseille, France; Centre Alexis Vautrin, Nancy, France; Centre Oscar Lambret, Lille, France; Centre René Gauducheau, Nantes, France; Novartis, Rueil-Malmaison, France; Hôpital Edouard Herriot, Lyon, France
| | - A. Adenis
- Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre Leon Berard, Lyon, France; Hôpital La Timone, Marseille, France; Centre Alexis Vautrin, Nancy, France; Centre Oscar Lambret, Lille, France; Centre René Gauducheau, Nantes, France; Novartis, Rueil-Malmaison, France; Hôpital Edouard Herriot, Lyon, France
| | - E. Bonpas
- Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre Leon Berard, Lyon, France; Hôpital La Timone, Marseille, France; Centre Alexis Vautrin, Nancy, France; Centre Oscar Lambret, Lille, France; Centre René Gauducheau, Nantes, France; Novartis, Rueil-Malmaison, France; Hôpital Edouard Herriot, Lyon, France
| | - D. Perol
- Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre Leon Berard, Lyon, France; Hôpital La Timone, Marseille, France; Centre Alexis Vautrin, Nancy, France; Centre Oscar Lambret, Lille, France; Centre René Gauducheau, Nantes, France; Novartis, Rueil-Malmaison, France; Hôpital Edouard Herriot, Lyon, France
| | - P. Berthaud
- Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre Leon Berard, Lyon, France; Hôpital La Timone, Marseille, France; Centre Alexis Vautrin, Nancy, France; Centre Oscar Lambret, Lille, France; Centre René Gauducheau, Nantes, France; Novartis, Rueil-Malmaison, France; Hôpital Edouard Herriot, Lyon, France
| | - J. Blay
- Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre Leon Berard, Lyon, France; Hôpital La Timone, Marseille, France; Centre Alexis Vautrin, Nancy, France; Centre Oscar Lambret, Lille, France; Centre René Gauducheau, Nantes, France; Novartis, Rueil-Malmaison, France; Hôpital Edouard Herriot, Lyon, France
| |
Collapse
|
6
|
Vassal G, Geoerger B, Le Deley M, Doz F, Pichon F, Frappaz D, Gentet J, Landman-Parker J, Berthaud P, Morland B. ITCC phase II study of imatinib mesylate in children with solid tumors expressing imatinib-sensitive tyrosine kinase receptors. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.9003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9003 Background: Imatinib mesylate inhibits selectively specific activations of the platelet-derived growth factor receptor (PDGFR), c-KIT and BCR/ABL tyrosine kinases and is approved for the treatment of chronic myeloid leukemia and gastro-intestinal stromal tumors (GIST). This study evaluated efficacy of imatinib in solid childhood tumors. Methods: Phase II study of imatinib as single agent in children and adolescents with refractory or relapsing solid tumor expressing at least one of the receptors. Patients were to be treated at 340 mg/m2, a dose escalation allowed to 440 mg/m2 after 2 months in case of insignificant improvement. C-KIT, PDGFRα and β expression was determined on archive tissue sections by immunohistochemistry prior to study entry. Gene mutations, pharmacokinetics, pharmacogenetics, and positron emission tomography imaging were assessed. Results: 36 patients, 21 boys, median age 13.7 years (2.2–22.5 y), 12 with brain tumors, 6 fibromatosis, 8 mesenchymal/bone tumors, and 10 other solid tumors, including 1 GIST and 3 chordoma, were treated at 340 mg/m2 daily during a total of 168 months (median 1.9 month/patient, range 0.5–19). 18/36 expressed c-KIT, 10 PDGFRα, 21 PDGRβ; 12 expressed more than one receptor. Ten patients were escalated to 440 mg/m2 due to lack of efficacy. During the 1st month, 17 patients experienced mild toxicity (grade 1 and 2) related to study treatment: gastro-intestinal (n=22), face edema (n=7), asthenia (n=5), tumor induration (n=2), skin toxicity (n=2), thrombocytopenia (n=1). No partial or complete response was observed; 5 patients (2 fibromatosis, 1 GIST, 1 medulloblastoma, 1 pseudo-inflammatory tumor) experiencing durable stable disease have been under treatment for more than 12 months. Interesting tumor stabilization during 10 and 7 months, respectively, was achieved in a brain stem glioma and a renal carcinoma. Glucose uptake on 18FDG PET scan was reduced in a chordoma, although the child progressed and died due to disease. Pharmacokinetic and genetic data are currently evaluated. Conclusions: Imatinib as single agent was well tolerated, but—as used in our study —failed to show measurable anti-tumor effects according the standard criteria in the pediatric malignancies studied. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- G. Vassal
- Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Hôpital Enfants—La Timone, Marseille, France; Hôpital Trousseau, Paris, France; Novartis Pharmaceuticals, Reuil-Malmaison, France; Children’s Hospital Birmingham, London, United Kingdom
| | - B. Geoerger
- Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Hôpital Enfants—La Timone, Marseille, France; Hôpital Trousseau, Paris, France; Novartis Pharmaceuticals, Reuil-Malmaison, France; Children’s Hospital Birmingham, London, United Kingdom
| | - M. Le Deley
- Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Hôpital Enfants—La Timone, Marseille, France; Hôpital Trousseau, Paris, France; Novartis Pharmaceuticals, Reuil-Malmaison, France; Children’s Hospital Birmingham, London, United Kingdom
| | - F. Doz
- Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Hôpital Enfants—La Timone, Marseille, France; Hôpital Trousseau, Paris, France; Novartis Pharmaceuticals, Reuil-Malmaison, France; Children’s Hospital Birmingham, London, United Kingdom
| | - F. Pichon
- Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Hôpital Enfants—La Timone, Marseille, France; Hôpital Trousseau, Paris, France; Novartis Pharmaceuticals, Reuil-Malmaison, France; Children’s Hospital Birmingham, London, United Kingdom
| | - D. Frappaz
- Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Hôpital Enfants—La Timone, Marseille, France; Hôpital Trousseau, Paris, France; Novartis Pharmaceuticals, Reuil-Malmaison, France; Children’s Hospital Birmingham, London, United Kingdom
| | - J. Gentet
- Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Hôpital Enfants—La Timone, Marseille, France; Hôpital Trousseau, Paris, France; Novartis Pharmaceuticals, Reuil-Malmaison, France; Children’s Hospital Birmingham, London, United Kingdom
| | - J. Landman-Parker
- Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Hôpital Enfants—La Timone, Marseille, France; Hôpital Trousseau, Paris, France; Novartis Pharmaceuticals, Reuil-Malmaison, France; Children’s Hospital Birmingham, London, United Kingdom
| | - P. Berthaud
- Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Hôpital Enfants—La Timone, Marseille, France; Hôpital Trousseau, Paris, France; Novartis Pharmaceuticals, Reuil-Malmaison, France; Children’s Hospital Birmingham, London, United Kingdom
| | - B. Morland
- Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Leon Berard, Lyon, France; Hôpital Enfants—La Timone, Marseille, France; Hôpital Trousseau, Paris, France; Novartis Pharmaceuticals, Reuil-Malmaison, France; Children’s Hospital Birmingham, London, United Kingdom
| |
Collapse
|
7
|
Kerob D, Porcher R, Verola O, Dalle S, Maubec E, Servant JM, Calvo F, Berthaud P, Mathieu-Boue A, Pedeutour F, Lebbe C. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: Preliminary results of a multicentric phase II study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.9550] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9550 Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue sarcoma of intermediate malignant potential. Treatment relies on a wide local excision with negative margin with frequent need of reconstructive surgery. A translocation between chromosomes 17 and 22 that places PDGFB under the control of the collagen 1A1 promoter is present in > 90% of the cases leading to an up regulation of PDGFB expression and activation of the tyrosinase kinase PDGFRβ. Anecdotal reports and a report on 8 patients suggest that Imatinib mesylate (IM) has a clinical interest in DFSP. The primary aim of this phase II multicentric study is to define the percentage of clinical responders (RECIST) to a preoperative 2 months 600mg IM daily before wide local excision. The secondary goals are to determine tolerance, imaging (ultrasound and MRI), pathological responses and to analyse PDGFRβ phosphorylation status and tumour cell apoptosis in sequential tissues specimen. Fifteen adults suffering from primary or recurrent DFSP have been included since July 2004. All tumors had a diameter ≥2cm. A flexible design with interim analysis after recruitment of 6 patients was used. 18 to 28 patients had to be enrolled to detect a 30% response rate with power 80%, using a one-sided test against 5%, at the 2.5% level. Three men and 3 women, median age 48.4 years [23; 72.5] have been evaluated. Tumour characteristics are as follows : primary (n=4), recurrence (n=2) all involved trunk, median size 5.75cm [2.5–12]. Tolerance was good apart from grade 1 facial oedema (n=6) grade 2 maculopapular rash (n=1), grade 1 asthenia (n=1), grade 1 pyrosis (n=2). Translocation t(17;22) was detected in all tumours. A partial response was achieved in 3 of 6 patients. The median relative decrease of tumor in the PR and non responder patients was of 21.9% [−3.3; 72.0]. Histological analysis revealed a global decrease of cellularity often accompanied with a CD34 loss of expression, a fibrosis and mild peripheral lymphoid infiltrates. No evidence of apoptosis on tissue specimen after surgery was observed using TUNEL. These encouraging interim results weresubmitted to an independent committee who allowed to continue the trial and to include a total of 24 patients in order to reduce the confidence interval of response rate. [Table: see text]
Collapse
Affiliation(s)
- D. Kerob
- Hôpital Saint-Louis, Paris, France; Lyon, France; Novartis Pharmaceuticals, Rueil Malmaison, France; Cytogenetic Laboratory, Nice, France
| | - R. Porcher
- Hôpital Saint-Louis, Paris, France; Lyon, France; Novartis Pharmaceuticals, Rueil Malmaison, France; Cytogenetic Laboratory, Nice, France
| | - O. Verola
- Hôpital Saint-Louis, Paris, France; Lyon, France; Novartis Pharmaceuticals, Rueil Malmaison, France; Cytogenetic Laboratory, Nice, France
| | - S. Dalle
- Hôpital Saint-Louis, Paris, France; Lyon, France; Novartis Pharmaceuticals, Rueil Malmaison, France; Cytogenetic Laboratory, Nice, France
| | - E. Maubec
- Hôpital Saint-Louis, Paris, France; Lyon, France; Novartis Pharmaceuticals, Rueil Malmaison, France; Cytogenetic Laboratory, Nice, France
| | - J. M. Servant
- Hôpital Saint-Louis, Paris, France; Lyon, France; Novartis Pharmaceuticals, Rueil Malmaison, France; Cytogenetic Laboratory, Nice, France
| | - F. Calvo
- Hôpital Saint-Louis, Paris, France; Lyon, France; Novartis Pharmaceuticals, Rueil Malmaison, France; Cytogenetic Laboratory, Nice, France
| | - P. Berthaud
- Hôpital Saint-Louis, Paris, France; Lyon, France; Novartis Pharmaceuticals, Rueil Malmaison, France; Cytogenetic Laboratory, Nice, France
| | - A. Mathieu-Boue
- Hôpital Saint-Louis, Paris, France; Lyon, France; Novartis Pharmaceuticals, Rueil Malmaison, France; Cytogenetic Laboratory, Nice, France
| | - F. Pedeutour
- Hôpital Saint-Louis, Paris, France; Lyon, France; Novartis Pharmaceuticals, Rueil Malmaison, France; Cytogenetic Laboratory, Nice, France
| | - C. Lebbe
- Hôpital Saint-Louis, Paris, France; Lyon, France; Novartis Pharmaceuticals, Rueil Malmaison, France; Cytogenetic Laboratory, Nice, France
| |
Collapse
|
8
|
Penel N, Le Cesne A, Bui B, Tubiana-Hulin M, Guillemet C, Cupissol D, Berthaud P, Mahier C, Pérol D, Blay J. Imatinib for the treatment of aggressive fibromatosis (desmoid tumors) failing local treatment. A phase II trial of the French Sarcoma Group. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.9516] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9516 Background: Background: Aggressive fibromatosis/desmoid tumors (AF/DT) are rare tumors with loco regional spreading. Few options are available when local treatments have failed. Although cytotoxic agents, hormonal treatment have been reported to induced responses and tumor control in some patients, only few prospective phase II trials have been reported in the literature. Recently, antitumor activity of imatinib in AF/DT was reported. We report a phase II trial of imatinib in AF/DT after failure of local treatment options. Methods: Pts ≥ 18 years with advanced AF/DT from all sites in whom neither surgery nor radiotherapy was possible were eligible. The principal inclusion criterias were: disease not amenable to surgery and/or radiation with curative intent, systemic pre-treatments allowed and presence of a measurable lesion with evidence of progression. Imatinib was given at the dose of 400 mg/d and increased to 800 mg/d if progression. Primary endpoint was the rate of progression free at 3 months. A two stages Simon‘s optimal design was used with p0=10%, p1=30%, α=0.05 and 90% power. 18 pts were scheduled to be recruited in the first stage for a total of 35 evaluable pts. Results: Between 09/2004 and 10/2005, 40 pts were included in 15 centers. The median age was 40 years (range 20–72) with 26% males. Primary sites were extra abdominal, mesenteric, abdominal wall in 79, 15, and 6% respectively. 15% patients had not been operated previously and 17% undergone radiotherapy. Prior systemic treatments were: NSAID, hormonal therapy or chemotherapy in 34, 46 and 23%, respectively. Median treatment duration was 4 months (range 0–12). No G4 toxicity was reported. Toxicities (G1–3) were notified for 30 pts including asthenias (70%), nauseas (53%), diarrheas, oedema (40%). G3 toxicities were abdominal pain (10%), rash, nausea, vomiting and asthenia (7%). At 3 months, 22 pts (55%) were evaluable with 1 CR, 17 SD and 4PD. As of December 2005, 7 of the 40 pts had progressed. After progression, dose was stopped in 2 pts and increased to 800mg in 5 pts with 2 tumor control following dose-escalation. Conclusions: Imatinib induces prolonged disease stabilization in the majority of evaluable patients with AF/DT in whom no local treatment option was available. [Table: see text]
Collapse
Affiliation(s)
- N. Penel
- Oscar Lambret Cancer Center, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Bergonié, Bordeaux, France; Centre René Huguenin, Saint Cloud, France; Centre Henri Becquerel, Rouen, France; Centre Val d’Aurelle, Montpellier, France; FNCLCC, Paris, France; Centre Leon Berard, Lyon, France; Hôpital Edouard Herriot, Lyon, France
| | - A. Le Cesne
- Oscar Lambret Cancer Center, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Bergonié, Bordeaux, France; Centre René Huguenin, Saint Cloud, France; Centre Henri Becquerel, Rouen, France; Centre Val d’Aurelle, Montpellier, France; FNCLCC, Paris, France; Centre Leon Berard, Lyon, France; Hôpital Edouard Herriot, Lyon, France
| | - B. Bui
- Oscar Lambret Cancer Center, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Bergonié, Bordeaux, France; Centre René Huguenin, Saint Cloud, France; Centre Henri Becquerel, Rouen, France; Centre Val d’Aurelle, Montpellier, France; FNCLCC, Paris, France; Centre Leon Berard, Lyon, France; Hôpital Edouard Herriot, Lyon, France
| | - M. Tubiana-Hulin
- Oscar Lambret Cancer Center, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Bergonié, Bordeaux, France; Centre René Huguenin, Saint Cloud, France; Centre Henri Becquerel, Rouen, France; Centre Val d’Aurelle, Montpellier, France; FNCLCC, Paris, France; Centre Leon Berard, Lyon, France; Hôpital Edouard Herriot, Lyon, France
| | - C. Guillemet
- Oscar Lambret Cancer Center, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Bergonié, Bordeaux, France; Centre René Huguenin, Saint Cloud, France; Centre Henri Becquerel, Rouen, France; Centre Val d’Aurelle, Montpellier, France; FNCLCC, Paris, France; Centre Leon Berard, Lyon, France; Hôpital Edouard Herriot, Lyon, France
| | - D. Cupissol
- Oscar Lambret Cancer Center, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Bergonié, Bordeaux, France; Centre René Huguenin, Saint Cloud, France; Centre Henri Becquerel, Rouen, France; Centre Val d’Aurelle, Montpellier, France; FNCLCC, Paris, France; Centre Leon Berard, Lyon, France; Hôpital Edouard Herriot, Lyon, France
| | - P. Berthaud
- Oscar Lambret Cancer Center, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Bergonié, Bordeaux, France; Centre René Huguenin, Saint Cloud, France; Centre Henri Becquerel, Rouen, France; Centre Val d’Aurelle, Montpellier, France; FNCLCC, Paris, France; Centre Leon Berard, Lyon, France; Hôpital Edouard Herriot, Lyon, France
| | - C. Mahier
- Oscar Lambret Cancer Center, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Bergonié, Bordeaux, France; Centre René Huguenin, Saint Cloud, France; Centre Henri Becquerel, Rouen, France; Centre Val d’Aurelle, Montpellier, France; FNCLCC, Paris, France; Centre Leon Berard, Lyon, France; Hôpital Edouard Herriot, Lyon, France
| | - D. Pérol
- Oscar Lambret Cancer Center, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Bergonié, Bordeaux, France; Centre René Huguenin, Saint Cloud, France; Centre Henri Becquerel, Rouen, France; Centre Val d’Aurelle, Montpellier, France; FNCLCC, Paris, France; Centre Leon Berard, Lyon, France; Hôpital Edouard Herriot, Lyon, France
| | - J. Blay
- Oscar Lambret Cancer Center, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Bergonié, Bordeaux, France; Centre René Huguenin, Saint Cloud, France; Centre Henri Becquerel, Rouen, France; Centre Val d’Aurelle, Montpellier, France; FNCLCC, Paris, France; Centre Leon Berard, Lyon, France; Hôpital Edouard Herriot, Lyon, France
| |
Collapse
|
9
|
Le Cesne A, Perol D, Ray-Coquard I, Bui B, Duffaud F, Rios M, Coindre JM, Emile JF, Berthaud P, Blay JY. Interruption of imatinib (IM) in GIST patients with advanced disease: Updated results of the prospective French Sarcoma Group randomized phase III trial on survival and quality of life. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9031] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Le Cesne
- Inst Gustave Roussy, Villejuif, France; Ctr Léon Bérard, Lyon, France; Inst Bergonié, Bordeaux, France; Hosp La Timone, Marseille, France; Ctr Alexis Vautrin, Nancy, France; Ambroise Paré, Boulogne, France; Novartis Pharma, Rueil Malmaison, France
| | - D. Perol
- Inst Gustave Roussy, Villejuif, France; Ctr Léon Bérard, Lyon, France; Inst Bergonié, Bordeaux, France; Hosp La Timone, Marseille, France; Ctr Alexis Vautrin, Nancy, France; Ambroise Paré, Boulogne, France; Novartis Pharma, Rueil Malmaison, France
| | - I. Ray-Coquard
- Inst Gustave Roussy, Villejuif, France; Ctr Léon Bérard, Lyon, France; Inst Bergonié, Bordeaux, France; Hosp La Timone, Marseille, France; Ctr Alexis Vautrin, Nancy, France; Ambroise Paré, Boulogne, France; Novartis Pharma, Rueil Malmaison, France
| | - B. Bui
- Inst Gustave Roussy, Villejuif, France; Ctr Léon Bérard, Lyon, France; Inst Bergonié, Bordeaux, France; Hosp La Timone, Marseille, France; Ctr Alexis Vautrin, Nancy, France; Ambroise Paré, Boulogne, France; Novartis Pharma, Rueil Malmaison, France
| | - F. Duffaud
- Inst Gustave Roussy, Villejuif, France; Ctr Léon Bérard, Lyon, France; Inst Bergonié, Bordeaux, France; Hosp La Timone, Marseille, France; Ctr Alexis Vautrin, Nancy, France; Ambroise Paré, Boulogne, France; Novartis Pharma, Rueil Malmaison, France
| | - M. Rios
- Inst Gustave Roussy, Villejuif, France; Ctr Léon Bérard, Lyon, France; Inst Bergonié, Bordeaux, France; Hosp La Timone, Marseille, France; Ctr Alexis Vautrin, Nancy, France; Ambroise Paré, Boulogne, France; Novartis Pharma, Rueil Malmaison, France
| | - J. M. Coindre
- Inst Gustave Roussy, Villejuif, France; Ctr Léon Bérard, Lyon, France; Inst Bergonié, Bordeaux, France; Hosp La Timone, Marseille, France; Ctr Alexis Vautrin, Nancy, France; Ambroise Paré, Boulogne, France; Novartis Pharma, Rueil Malmaison, France
| | - J. F. Emile
- Inst Gustave Roussy, Villejuif, France; Ctr Léon Bérard, Lyon, France; Inst Bergonié, Bordeaux, France; Hosp La Timone, Marseille, France; Ctr Alexis Vautrin, Nancy, France; Ambroise Paré, Boulogne, France; Novartis Pharma, Rueil Malmaison, France
| | - P. Berthaud
- Inst Gustave Roussy, Villejuif, France; Ctr Léon Bérard, Lyon, France; Inst Bergonié, Bordeaux, France; Hosp La Timone, Marseille, France; Ctr Alexis Vautrin, Nancy, France; Ambroise Paré, Boulogne, France; Novartis Pharma, Rueil Malmaison, France
| | - J. Y. Blay
- Inst Gustave Roussy, Villejuif, France; Ctr Léon Bérard, Lyon, France; Inst Bergonié, Bordeaux, France; Hosp La Timone, Marseille, France; Ctr Alexis Vautrin, Nancy, France; Ambroise Paré, Boulogne, France; Novartis Pharma, Rueil Malmaison, France
| |
Collapse
|
10
|
Ray-Coquard I, Pérol D, Bui BNG, Duffaud F, Rios M, Viens P, Robert C, Berthaud P, Le Cesne A, Blay For The Group Sarcome Francais JY. Prognostic factors for progression free and overall survival in advanced GIST: Results from the BFR14 phase III trial of the French Sarcoma Group. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- I. Ray-Coquard
- Ctr Léon Bérard, Lyon, France; Inst Bergonie, Bordeaux, France; Hosp de la Timone, Marseille, France; Ctr Alexis Vautrin, Nancy, France; Inst Paoli Calmettes, Marseille, France; Inst Gustave Roussy, Villejuif, France; Novartis Pharma, Rueil Malmaison, France; Inserm U590 Ctr Léon Bérard, Lyon, France
| | - D. Pérol
- Ctr Léon Bérard, Lyon, France; Inst Bergonie, Bordeaux, France; Hosp de la Timone, Marseille, France; Ctr Alexis Vautrin, Nancy, France; Inst Paoli Calmettes, Marseille, France; Inst Gustave Roussy, Villejuif, France; Novartis Pharma, Rueil Malmaison, France; Inserm U590 Ctr Léon Bérard, Lyon, France
| | - B. N. G. Bui
- Ctr Léon Bérard, Lyon, France; Inst Bergonie, Bordeaux, France; Hosp de la Timone, Marseille, France; Ctr Alexis Vautrin, Nancy, France; Inst Paoli Calmettes, Marseille, France; Inst Gustave Roussy, Villejuif, France; Novartis Pharma, Rueil Malmaison, France; Inserm U590 Ctr Léon Bérard, Lyon, France
| | - F. Duffaud
- Ctr Léon Bérard, Lyon, France; Inst Bergonie, Bordeaux, France; Hosp de la Timone, Marseille, France; Ctr Alexis Vautrin, Nancy, France; Inst Paoli Calmettes, Marseille, France; Inst Gustave Roussy, Villejuif, France; Novartis Pharma, Rueil Malmaison, France; Inserm U590 Ctr Léon Bérard, Lyon, France
| | - M. Rios
- Ctr Léon Bérard, Lyon, France; Inst Bergonie, Bordeaux, France; Hosp de la Timone, Marseille, France; Ctr Alexis Vautrin, Nancy, France; Inst Paoli Calmettes, Marseille, France; Inst Gustave Roussy, Villejuif, France; Novartis Pharma, Rueil Malmaison, France; Inserm U590 Ctr Léon Bérard, Lyon, France
| | - P. Viens
- Ctr Léon Bérard, Lyon, France; Inst Bergonie, Bordeaux, France; Hosp de la Timone, Marseille, France; Ctr Alexis Vautrin, Nancy, France; Inst Paoli Calmettes, Marseille, France; Inst Gustave Roussy, Villejuif, France; Novartis Pharma, Rueil Malmaison, France; Inserm U590 Ctr Léon Bérard, Lyon, France
| | - C. Robert
- Ctr Léon Bérard, Lyon, France; Inst Bergonie, Bordeaux, France; Hosp de la Timone, Marseille, France; Ctr Alexis Vautrin, Nancy, France; Inst Paoli Calmettes, Marseille, France; Inst Gustave Roussy, Villejuif, France; Novartis Pharma, Rueil Malmaison, France; Inserm U590 Ctr Léon Bérard, Lyon, France
| | - P. Berthaud
- Ctr Léon Bérard, Lyon, France; Inst Bergonie, Bordeaux, France; Hosp de la Timone, Marseille, France; Ctr Alexis Vautrin, Nancy, France; Inst Paoli Calmettes, Marseille, France; Inst Gustave Roussy, Villejuif, France; Novartis Pharma, Rueil Malmaison, France; Inserm U590 Ctr Léon Bérard, Lyon, France
| | - A. Le Cesne
- Ctr Léon Bérard, Lyon, France; Inst Bergonie, Bordeaux, France; Hosp de la Timone, Marseille, France; Ctr Alexis Vautrin, Nancy, France; Inst Paoli Calmettes, Marseille, France; Inst Gustave Roussy, Villejuif, France; Novartis Pharma, Rueil Malmaison, France; Inserm U590 Ctr Léon Bérard, Lyon, France
| | - J. Y. Blay For The Group Sarcome Francais
- Ctr Léon Bérard, Lyon, France; Inst Bergonie, Bordeaux, France; Hosp de la Timone, Marseille, France; Ctr Alexis Vautrin, Nancy, France; Inst Paoli Calmettes, Marseille, France; Inst Gustave Roussy, Villejuif, France; Novartis Pharma, Rueil Malmaison, France; Inserm U590 Ctr Léon Bérard, Lyon, France
| |
Collapse
|
11
|
Tualle JM, Nghiêm HL, Schäfauer C, Berthaud P, Tinet E, Ettori D, Avrillier S. Time-resolved measurements from speckle interferometry. Opt Lett 2005; 30:50-52. [PMID: 15648634 DOI: 10.1364/ol.30.000050] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
We present time-resolved measurements by speckle interferometry of the light scattered by a liquid medium. Measurements were performed by use of reflectance geometry and are compared with results obtained in the same conditions with a femtosecond laser and a streak camera. The setup was also tested in vivo on the forearm of a human volunteer to demonstrate the potential utility of such a setup for biomedical applications.
Collapse
Affiliation(s)
- J M Tualle
- Laboratoire de Physique des Lasers (Centre National de la Recherche Scientifique, Unité Mixte de Recherche 7538), Université Paris 13, 99 Avenue J.-B. Clément, 93430 Villetaneuse, France.
| | | | | | | | | | | | | |
Collapse
|
12
|
Tardieu S, Brun-Srang C, Berthaud P, Michallet M, Guilhot F, Rousselot P, Sambuc R. P2-14 La prise en charge de la leucémie myéloïde chronique en France : Une étude transversale multicentrique sur 538 patients. Rev Epidemiol Sante Publique 2004. [DOI: 10.1016/s0398-7620(04)99236-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022] Open
|
13
|
Delbaldo C, Chatelut E, Ré M, Deroussent A, Mackrodt A, Jambu A, Berthaud P, Le Cesne A, Vassal G. 635 Inflammatory response might influence the pharmacokinetics (PK) and pharmacodynamics (PD) of Imatinib and CGP 74588 in patients with advanced gastro-intestinal-sarcoma (GIST). EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)80643-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
14
|
Gomez Abuin G, Lassalle M, Bonvalot S, Terrier P, Le Pechoux C, Vanel D, Robert C, Saghatchian M, Berthaud P, Le Cesne A. Intensive induction chemotherapy (API-AI regimen) followed by conservative surgery in adult patients with locally advanced soft tissue sarcoma (STS): Survival is predicted by the histological response. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.9036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | - P. Terrier
- Institut Gustave Roussy, Villejuif, France
| | | | - D. Vanel
- Institut Gustave Roussy, Villejuif, France
| | - C. Robert
- Institut Gustave Roussy, Villejuif, France
| | | | | | | |
Collapse
|
15
|
Duffaud F, Lecesne A, Ray-Coquard I, Bompass E, Assi K, Berthaud P, Ducimetiere F, Blay JY. Erythropoietin for anemia treatment of patients with GIST receiving imatinib. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.9046] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. Duffaud
- Hopital La Timone, Marseille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon Bérard, Lyon, France; Hopital Edouard Herriot, Lyon, France; Novartis Pharma, Rueil, France
| | - A. Lecesne
- Hopital La Timone, Marseille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon Bérard, Lyon, France; Hopital Edouard Herriot, Lyon, France; Novartis Pharma, Rueil, France
| | - I. Ray-Coquard
- Hopital La Timone, Marseille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon Bérard, Lyon, France; Hopital Edouard Herriot, Lyon, France; Novartis Pharma, Rueil, France
| | - E. Bompass
- Hopital La Timone, Marseille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon Bérard, Lyon, France; Hopital Edouard Herriot, Lyon, France; Novartis Pharma, Rueil, France
| | - K. Assi
- Hopital La Timone, Marseille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon Bérard, Lyon, France; Hopital Edouard Herriot, Lyon, France; Novartis Pharma, Rueil, France
| | - P. Berthaud
- Hopital La Timone, Marseille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon Bérard, Lyon, France; Hopital Edouard Herriot, Lyon, France; Novartis Pharma, Rueil, France
| | - F. Ducimetiere
- Hopital La Timone, Marseille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon Bérard, Lyon, France; Hopital Edouard Herriot, Lyon, France; Novartis Pharma, Rueil, France
| | - J.-Y. Blay
- Hopital La Timone, Marseille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon Bérard, Lyon, France; Hopital Edouard Herriot, Lyon, France; Novartis Pharma, Rueil, France
| |
Collapse
|
16
|
Blay JY, Berthaud P, Perol D, Ray-Coquard I, Bui B, Duffaud F, Braud AC, Rios M, Ducimetiere F, Le Cesne A. Continuous vs intermittent imatinib treatment in advanced GIST after one year: A prospective randomized phase III trial of the French Sarcoma Group. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.9006] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J.-Y. Blay
- Hop. E. Herriot & C. L. Berard, Lyon Cedex 08, France; Novartis Pharma, Rueil Malmaison, France; Centre Leon Berard, Lyon Cedex 08, France; Institut Bergonie, Bordeaux, France; Hopital de La Timone, Marseille, France; Institut Paoli Calmettes, Marseilles, France; Centre Alexis Vautrin, Nancy, France; Institut Gustave Roussy, Villejuif, France
| | - P. Berthaud
- Hop. E. Herriot & C. L. Berard, Lyon Cedex 08, France; Novartis Pharma, Rueil Malmaison, France; Centre Leon Berard, Lyon Cedex 08, France; Institut Bergonie, Bordeaux, France; Hopital de La Timone, Marseille, France; Institut Paoli Calmettes, Marseilles, France; Centre Alexis Vautrin, Nancy, France; Institut Gustave Roussy, Villejuif, France
| | - D. Perol
- Hop. E. Herriot & C. L. Berard, Lyon Cedex 08, France; Novartis Pharma, Rueil Malmaison, France; Centre Leon Berard, Lyon Cedex 08, France; Institut Bergonie, Bordeaux, France; Hopital de La Timone, Marseille, France; Institut Paoli Calmettes, Marseilles, France; Centre Alexis Vautrin, Nancy, France; Institut Gustave Roussy, Villejuif, France
| | - I. Ray-Coquard
- Hop. E. Herriot & C. L. Berard, Lyon Cedex 08, France; Novartis Pharma, Rueil Malmaison, France; Centre Leon Berard, Lyon Cedex 08, France; Institut Bergonie, Bordeaux, France; Hopital de La Timone, Marseille, France; Institut Paoli Calmettes, Marseilles, France; Centre Alexis Vautrin, Nancy, France; Institut Gustave Roussy, Villejuif, France
| | - B. Bui
- Hop. E. Herriot & C. L. Berard, Lyon Cedex 08, France; Novartis Pharma, Rueil Malmaison, France; Centre Leon Berard, Lyon Cedex 08, France; Institut Bergonie, Bordeaux, France; Hopital de La Timone, Marseille, France; Institut Paoli Calmettes, Marseilles, France; Centre Alexis Vautrin, Nancy, France; Institut Gustave Roussy, Villejuif, France
| | - F. Duffaud
- Hop. E. Herriot & C. L. Berard, Lyon Cedex 08, France; Novartis Pharma, Rueil Malmaison, France; Centre Leon Berard, Lyon Cedex 08, France; Institut Bergonie, Bordeaux, France; Hopital de La Timone, Marseille, France; Institut Paoli Calmettes, Marseilles, France; Centre Alexis Vautrin, Nancy, France; Institut Gustave Roussy, Villejuif, France
| | - A.-C. Braud
- Hop. E. Herriot & C. L. Berard, Lyon Cedex 08, France; Novartis Pharma, Rueil Malmaison, France; Centre Leon Berard, Lyon Cedex 08, France; Institut Bergonie, Bordeaux, France; Hopital de La Timone, Marseille, France; Institut Paoli Calmettes, Marseilles, France; Centre Alexis Vautrin, Nancy, France; Institut Gustave Roussy, Villejuif, France
| | - M. Rios
- Hop. E. Herriot & C. L. Berard, Lyon Cedex 08, France; Novartis Pharma, Rueil Malmaison, France; Centre Leon Berard, Lyon Cedex 08, France; Institut Bergonie, Bordeaux, France; Hopital de La Timone, Marseille, France; Institut Paoli Calmettes, Marseilles, France; Centre Alexis Vautrin, Nancy, France; Institut Gustave Roussy, Villejuif, France
| | - F. Ducimetiere
- Hop. E. Herriot & C. L. Berard, Lyon Cedex 08, France; Novartis Pharma, Rueil Malmaison, France; Centre Leon Berard, Lyon Cedex 08, France; Institut Bergonie, Bordeaux, France; Hopital de La Timone, Marseille, France; Institut Paoli Calmettes, Marseilles, France; Centre Alexis Vautrin, Nancy, France; Institut Gustave Roussy, Villejuif, France
| | - A. Le Cesne
- Hop. E. Herriot & C. L. Berard, Lyon Cedex 08, France; Novartis Pharma, Rueil Malmaison, France; Centre Leon Berard, Lyon Cedex 08, France; Institut Bergonie, Bordeaux, France; Hopital de La Timone, Marseille, France; Institut Paoli Calmettes, Marseilles, France; Centre Alexis Vautrin, Nancy, France; Institut Gustave Roussy, Villejuif, France
| |
Collapse
|
17
|
Monnerat C, Henriksson R, Le Chevalier T, Novello S, Berthaud P, Faivre S, Raymond E. Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Ann Oncol 2004; 15:316-23. [PMID: 14760128 DOI: 10.1093/annonc/mdh052] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND PKC412 (N-benzoyl-staurosporine), an oral inhibitor of protein kinase C, is capable of cell cycle inhibition and is endowed with anti-angiogenic properties. This dose-finding phase I study was designed to establish the maximum tolerated dose (MTD) of PKC412 when combined with cisplatin-gemcitabine. PATIENTS AND METHODS Escalating doses of PKC412 were given every day of a 4 week cycle with cisplatin 100 mg/m2 on day 2 and gemcitabine 1000 mg/m2 on days 1, 8 and 15 in patients with non-small-cell lung cancer. Dose escalation was based on a modified continuous reassessment method. RESULTS Twenty-three patients, assigned to four cohorts receiving PKC412 at a dose ranging from 25 to 150 mg/day were evaluable. Grade 3 diarrhea occurring in 3/4 patients at cycle 1 led us to define 150 mg/day as the MTD. The MTD based on multiple cycles was redefined as 100 mg/day, since prolonged grade 2-3 nausea/vomiting leading to treatment discontinuation occurred in 3/7 patients after repeated cycles. The next lower dose tested of 50 mg/day was therefore considered as the recommended dose for phase II trials. Among 33 cycles in eight patients, toxicity consisted of grade 1-2 diarrhea (12.5%) and asthenia (50%) with only one patient experiencing grade 3 headache at this dose level. A partial response was observed in three patients. CONCLUSIONS The results of the present study indicate that PKC412 at a dose of 50 mg/day can be safely added to cisplatin and gemcitabine in patients with advanced non-small-cell lung cancer.
Collapse
Affiliation(s)
- C Monnerat
- Department of Medicine, Institut Gustave-Roussy, Villejuif, France
| | | | | | | | | | | | | |
Collapse
|
18
|
Tabrizi R, Mahon FX, Cony Makhoul P, Lagarde V, Lacombe F, Berthaud P, Melo JV, Reiffers J, Belloc F. Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571. Leukemia 2002; 16:1154-9. [PMID: 12040447 DOI: 10.1038/sj.leu.2402498] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2001] [Accepted: 02/01/2002] [Indexed: 11/09/2022]
Abstract
The leukemogenic property of BCR-ABL in chronic myeloid leukemia (CML) is critically dependent on its protein tyrosine kinase activity. STI571 inhibits the BCR-ABL kinase activity, the growth and the viability of BCR-ABL expressing cells. In this study, we report the apoptotic effect of STI571 in combination with daunorubicin (DNR) on peripheral blood mononuclear cells from 11 CML patients and four BCR-ABL-positive cell lines: AR230, LAMA84, K562 and KCL22. Primary blast cells were identified by flow cytometry on the basis of their low CD45 expression. Nucleus fragmentation, exposure of phosphatidylserines and decrease in mitochondrial membrane potential were measured using acridine orange, FITC-annexin V and DiOC6(3), respectively, to evaluate apoptosis. On cell lines, the effect of DNR was negligible, whereas STI571 induced 10 to 35% of apoptosis in 18 h. STI571 sensitized AR230, LAMA84 and K562 cells to DNR when apoptosis was measured at the mitochondrial and membrane but not the nuclear levels. On CML blast cells, phosphatidyl serine exposure was significantly induced by both DNR and STI571 and was higher when these drugs were used in combination (P < 0.0003). However, the effects of this drug combination were only additive and no sensitization of blast cells to DNR by STI571 was observed. Interestingly, sensitization was evidenced in CML but not normal lymphocytes. These results suggest that other mechanisms additional to Bcr-Abl tyrosine kinase activity could be responsible for DNR resistance, and further investigations are needed to understand its origin.
Collapse
MESH Headings
- Antineoplastic Agents/pharmacology
- Apoptosis
- Benzamides
- Cell Nucleus/ultrastructure
- DNA Fragmentation
- Daunorubicin/pharmacology
- Drug Resistance, Neoplasm
- Enzyme Inhibitors/pharmacology
- Fusion Proteins, bcr-abl/antagonists & inhibitors
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/enzymology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Membrane Potentials/drug effects
- Mitochondria/drug effects
- Mitochondria/physiology
- Phosphatidylserines/analysis
- Piperazines/pharmacology
- Pyrimidines/pharmacology
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- R Tabrizi
- Laboratoire d'Hématologie, Hôpital Haut Lévêque, Pessac, France
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Monnerat C, Henriksson R, Raymond E, Berthaud P, Vicente-Azevedo J, Lavenius E, Dutreix C, Barbier N, Csermak K, Le Chevalier T. Phase I study of PKC412, a protein kinase C inhibitor, in combination with gemcitabine and cisplatin: Preliminary report of an ongoing phase I study. Lung Cancer 2000. [DOI: 10.1016/s0169-5002(00)80262-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
20
|
Derenne S, Amiot M, Barillé S, Collette M, Robillard N, Berthaud P, Harousseau JL, Bataille R. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 1999; 14:2048-56. [PMID: 10620064 DOI: 10.1359/jbmr.1999.14.12.2048] [Citation(s) in RCA: 137] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Bisphosphonates have recently been introduced in the therapeutic armamentarium for the long-term treatment of patients with multiple myeloma (MM). These pyrophosphate analogs not only reduce the occurrence of skeletal-related events but also provide patients with a clinical benefit and improve the survival of some of them. We investigated the effects of two bisphosphonates, pamidronate and zoledronate, on both myeloma cells and bone marrow stromal cells (BMSCs). We show here that both bisphosphonates induce both myeloma cell and BMSC apoptosis. Furthermore, at lower concentrations, they induce a significant inhibition (40% and 60%, respectively) of the constitutive production of interleukin-6 (IL-6) by BMSCs. We have recently shown that BMSCs produce MMP-1, the major metalloproteinase involved in the initiation of bone resorption, production up-regulated by IL-1beta. Here, we demonstrate that zoledronate significantly inhibits MMP-1 production by BMSCs stimulated with IL-1beta more efficiently than pamidronate. However, zoledronate and to a lesser extent pamidronate are responsible for an up-regulation of MMP-2 secretion by BMSCs. MMP-2 is involved both in bone resorption and in the metastatic process. In conclusion, the apoptosis of myeloma cells and BMSCs and the inhibition of both IL-6 and MMP-1 production induced by bisphosphonates, mainly zoledronate, could have antitumoral effects in patients with MM. However, the up-regulation of MMP-2 secretion observed in vitro suggests a putative risk of tumor cell dissemination in vivo when using these new potent bisphosphonates. This potentially deleterious effect could be abolished by combining bisphosphonates with metalloproteinase inhibitors.
Collapse
|
21
|
Lortholary A, Jadaud E, Berthaud P. [Bisphosphonates and bone metastases]. Bull Cancer 1999; 86:732-8. [PMID: 10519966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
Bisphosphonates, potent inhibitors of bone resorption have been emerging as the standard treatment of tumor-induced hypercalcemia during the 90's. All uncontrolled phase II studies up to 1992 had demonstrated efficacy in reducing morbidity in terms of bone pain, fracture and hypercalcemia. Other studies on intravenous bisphosphonates, with no other anti-tumor treatment, even demonstrated sclerosis of osteolytic breast cancer bone metastases. Randomised phase III studies only began after 1992. In multiple myeloma, one study with oral clodronate has reported a decrease in bone events and two other studies, one with intravenous pamidronate and the other with oral clodronate have both reported a decrease in skeletal events and bone pain. In breast cancer patients with bone metastases, five large studies have been reported: three with intravenous pamidronate, one with oral pamidronate and one with oral clodronate. All these studies have demonstrated the superiority of bisphosphonates over placebo on both bone pain and bone events, but have failed to show an increase in duration of survival. Bisphosphonates should therefore be considered as an important part of the palliative treatment in breast cancer patients with bone metastases. On the other hand, no definite conclusion can be drawn on the role of bisphosphonates in the treatment of prostatic carcinoma bone metastases yet. However, bisphosphonates should be considered as part of the standard therapy in managing painful lesions in patients with multiple myeloma, breast cancer and prostatic cancer. Nevertheless, further studies are needed with bisphosphonates in the adjuvant setting before bone metastases appear. Could new and more potent bisphosphonates such as zoledronate further reduce bone metastases morbidity?
Collapse
|
22
|
Le Chevalier T, Pujol J, Douilard J, Alberola V, Monnier A, Rivière A, Cigolari S, Ruffié P, Panizo A, Guillem V, Besson P, Danel P, Brisgand D, Berthaud P, Larriba J, Martinez A. 39 Six year follow up of the European Multicentre Randomised Study comparing Navelbine (NVB) alone vs NVB + Cisplatin (CDDP) vs Vindesine (VDS) + CDDP in 612 patients (pts) with advanced non-small cell lung cancer (NSCLC). Lung Cancer 1997. [DOI: 10.1016/s0169-5002(97)89318-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
23
|
Pujol JL, Douillard JY, Rivière A, Quoix E, Lagrange JL, Berthaud P, Bardonnet-Comte M, Polin V, Gautier V, Milleron B, Chomy F, Chomy P, Spaeth D, Le Chevalier T. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. J Clin Oncol 1997; 15:2082-9. [PMID: 9164221 DOI: 10.1200/jco.1997.15.5.2082] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
PURPOSE AND METHODS We investigated whether a high-dose chemotherapy regimen of cyclophosphamide 1,800 mg/m2, 4'-epidoxorubicin 60 mg/m2, etoposide 330 mg/m2, and cisplatin 120 mg/m2 given monthly for four cycles with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) support (5 micrograms/kg daily for 10 days) could improve the survival of patients with extensive-stage small-cell lung cancer (SCLC) compared with a standard-dose regimen (cyclophosphamide 1,200 mg/m2, 4'-epidoxorubicin 40 mg/m2, etoposide 225 mg/m2, and cisplatin 100 mg/m2) given monthly for six cycles. Planned cumulative doses of the drugs were the same in both treatment arms except for cisplatin (which was 80% in the higher-dose plus rhGM-CSF group). RESULTS At the time of the preplanned interim analysis, 125 patients, 60 in the standard-dose group and 65 in the higher-dose plus rhGM-CSF group, had entered the study; 116 were eligible, 55 in the standard-dose group and 61 in the higher-dose group. All patients were included in the analyses. The cumulative doses of each drug actually delivered were significantly higher in the standard-dose group. No difference in response rates was observed between the two groups. There were significantly greater hematologic toxicities, documented infections, and transfusions of RBCs and platelets in the higher-dose plus rhGM-CSF group. Patients in this group proved to have a shorter survival duration and a shorter time to relapse than patients in the standard-dose group (median overall survival: standard-dose, 10.8 months; higher-dose, 8.9 months; log-rank test with adjustment for prognostic variables, P = .0005; respective probabilities of relapse at 1 year, 77 +/- 0.6 and 96 +/- 2.2; log-rank test, P = .013). CONCLUSION A 50% increase in dose-intensity for this four-drug regimen could not be achieved with GM-CSF due to excessive toxicity in patients with extensive-stage SCLC.
Collapse
Affiliation(s)
- J L Pujol
- Hôpital Universitaire Arnaud de Villeneuve, Montpellier, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Pignon B, Witz F, Desablens B, Leprise PY, Francois S, Linassier C, Berthou C, Caillot D, Lioure B, Cahn JY, Casassus P, Sadoun A, Audhuy B, Guyotat D, Briere J, Vilque JP, Baranger L, Polin V, Berthaud P, Hurteloup P, Herve P, Harousseau JL. Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam Group. Br J Haematol 1996; 94:333-41. [PMID: 8759894 DOI: 10.1046/j.1365-2141.1996.d01-1803.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
From December 1987 to June 1992, 251 patients aged 50-65 with de novo acute myelogenous leukaemia (AML) were recruited to a multi-institutional randomized clinical trial. Induction therapy consisted of Ara-C (200 mg/ m2, continuous infusion, days 1-7) with either zorubicin (ZRB) (200 mg/m2, i.v., days 1-4) or idarubicin (IDR) (8 mg/ m2, i.v., days 1-5). Consolidation therapy consisted of a single course of intensive chemotherapy with high-dose Ara-C (3 g/m2, 3 h infusion, q 12 h, days 1-4) and m-Amsa (100 mg/m2/d, i.v., days 5-7). The complete remission (CR) rate was (73%) with Ara-C/ IDR versus (60%) with Ara-C/ZRB (P = 0.033). In multivariate analysis, factors found to be significant in predicting CR were normal karyotype and treatment with IDR. With a median follow-up of 73 months, the median disease-free survival (DFS) duration of all CR patients and the probability of CR at 6 years were 17 months and 29%. In multivariate analysis the only factor associated with an increased DFS duration was a normal karyotype. The median event-free survival (EFS) duration for all evaluable patients and the median overall survival duration for all eligible patients were respectively 7 and 12 months without any difference between induction arms. The study shows that in patients aged 50-65 idarabicin is more effective than zorubicin for remission induction. However, the type of anthracycline did not influence overall survival duration. Using a unique consolidation course, we observed a prolonged DFS which compares favourably with results obtained with more prolonged consolidation therapy or maintenance treatment.
Collapse
Affiliation(s)
- B Pignon
- Unité d'Hématologie Clinique, Hôpital R. Debré Reims, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Dufour P, Mors R, Berthaud P, Lamy T, Bergerat JP, Herbrecht R, Maloisel F, Audhuy B, Lioure B, Giron C, Hurteloup P, Oberling F. Idarubicin and high dose cytarabine: a new salvage treatment for refractory or relapsing non-Hodgkin's lymphoma. Leuk Lymphoma 1996; 22:329-34. [PMID: 8819082 DOI: 10.3109/10428199609051764] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Twenty three patients with relapsing (n = 11) or refractory (n = 12) non-Hodgkin's lymphoma (NHL) to one or two prior anthracycline based combination chemotherapy regimens were treated as second or third line regimen with 3 induction cycles of Idarubicin (IDA) (7 mg/m2/d i.v. d1-d3) and high dose cytarabine (HD Ara-C) (1 g/m2/12 h i.v. d1-d3), each cycle was repeated every 3 weeks. Responding patients received a maintenance therapy with monthly cycles of IDA: 15 mg/m2 d1-d3, Etoposide 100 mg/m2 d1-d3, both by oral route. Twenty two patients are evaluable and we observed 13 CR and 1 PR with an overall response rate of 61% (14/23: 95% Cl = 38.5% 80.3%). The median time to progression was 32 months (6.5 - 63 + m.). The response rate to IDA-HD Ara C was not different for patients with (n = 14) or without (n = 9) objective response to the last prior therapy. The main toxicity was hematological: all patients experienced grade 4 neutropenia and 22 patients had grade 4 thrombopenia, but there were no toxic deaths. IDA and HD-Ara-C combination is highly effective in refractory or relapsed. NHL. As hematological toxicity was the limiting factor for further escalation of dose-intensity, further studies might include hematopoietic growth factors support in the therapeutic scheme.
Collapse
Affiliation(s)
- P Dufour
- Département Onco-Hématologie, Hôpitaux, Universitaires de Strasbourg, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Le Chevalier T, Brisgand D, Pujol JL, Douillard JY, Monnier A, Rivière A, Chomy P, Le Groumellec A, Ruffie P, Gottfried M, Gaspard MH, Chevreau C, Alberola V, Cigolari S, Besson F, Martinez A, Besenval M, Berthaud P, Tursz T. [Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer]. Bull Cancer 1996; 83:385-94. [PMID: 8680091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The combination of vindesine and cisplatin is considered a reference regimen in advanced NSCLC which has yielded a significant improvement in the duration of survival. A phase II study of a new semi-synthetic vinca alkaloid, Navelbine, reported an unusually high 29% response rate in stage III-IV NSCLC and a phase I-II study established the feasibility of the combination of Navelbine and cisplatin. We, therefore, designed a prospective randomized trial to compare Navelbine and cisplatin (NVB-P) to vindesine and cisplatin (VDS-P) and to evaluate whether the best of these regimens affords a survival benefit compared to Navelbine alone (NVB), an outpatient regimen. Forty-five centers included 612 patients in this study: 206 in NVB-P, 200 in VDS-P and 206 in NVB. Navelbine was given at a dose of 30 mg/m2 weekly, cisplatin at 120 mg/m2 on day 1, day 29 and then every 6 weeks and vindesine at 3 mg/m2 weekly for 6 weeks and then every other week. Treatment was continued until progression or toxicity. Patients' characteristics were similar in the three groups with 59% of patients presenting with metastatic disease. An objective response rate was observed in 30% of patients in NVB-P versus 19% in VDS-P (P = .02) and 14% in NVB (P < .001). The median duration of survival was 40 weeks in NVB-P compared to 32 weeks in VDS-P and 31 weeks in NVB. The comparison of survival between the three groups demonstrated an advantage for NVB-P compared to VDS-P (P = .04) and NVB (P = .02). Neutropenia was significantly higher in the NVB-P group (P < .001) and neurotoxicity more frequent with VDS-P (P < .004). Since our results have demonstrated that NVB-P yields a longer survival duration and a higher response rate than VDS-P or NVB alone, with acceptable toxicity, this combination should be considered a reference regimen in advanced NSCLC.
Collapse
|
27
|
Reiffers J, Huguet F, Stoppa AM, Molina L, Marit G, Attal M, Gastaut JA, Michallet M, Lepeu G, Broustet A, Pris J, Maraninchi D, Hollard D, Fabères C, Mercier M, Hurteloup P, Danel P, Tellier Z, Berthaud P. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia 1996; 10:389-95. [PMID: 8642852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
A prospective randomized study was conducted comparing the efficacy and toxicity of two anthracyclines for the treatment of patients with acute myeloid leukemia (AML) between 55 and 75 years. A total of 220 patients were randomized to receive as induction chemotherapy cytosine arabinoside (Ara-C: 100 mg/m2/day; continuous infusion for 7 days) combined with either daunorubicin (DNR: 50 mg/m2/day, i.v. bolus for 3 days) (n=108) or idarubicin (IDA: 8 mg/m2/day, i.v. bolus for 5 days) (n=112). The complete remission (CR) rate was similar (P=0.296) after IDA (76/112; 68%) and DNR (66/108; 61%) (P=0.3). For patients aged 55-65, the CR rate was significantly higher after IDA (39/47; 83%) than after DNR (29/50; 58%) (P=0.007). Persistent leukemia was more frequent after DNR (26/108) than after IDA (13/112; P=0.015). Hematological and extra-hematological toxicities were similar. The CR patients were given a consolidation course of chemotherapy with Ara-C: 50 mg/m2/12 h, subcutaneously for 5 days, combined with either DNR:30 mg m2/day, i.v. bolus for 3 days or IDA:8 mg/m2/day i.v. bolus for 3 days according to the initial randomization, and then received a continuous maintenance treatment for 2 years. The survival and disease-free survival (DFS) were similar in both groups; there was no difference in the risk of relapse. However, there was a trend for a longer event-free survival (EFS) in the IDA group than for the DNR patients (P=0.07). Our results seem to indicate that IDA is probably more efficient than DNR for AML patients between 55 and 75 years, and confirm the data published in other studies comparing prospectively IDA and DNR in adults.
Collapse
Affiliation(s)
- J Reiffers
- CHU Bordeaux, Hôpital Haut Lévêque, Service d'Hématologie, Pessac, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Pujol J, Douillard J, Rivière A, Poudenx M, Quoix E, Spaeth D, Chomy P, Lafitte J, Monnier A, Milleron B, Berthaud P, Le Chevalier T. 78 Dose intensive chemotherapy in patients with advanced small cell lung cancer (SCLC): Preliminary results of a multicenter randomized trial. Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)95330-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
29
|
Berthaud P, Eugène-Jolchine I, Spielmann M, Le Chevalier T, Tursz T. [Phase I trial of recombinant human granulocyte-macrophage colony stimulating factor. Results in patients with advanced tumors]. Bull Cancer 1993; 80:418-30. [PMID: 8173195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Fourteen patients with advanced solid tumors were included in a phase I trial of recombinant human E coli derived granulocyte-macrophage colony-stimulating factor (GM-CSF) given daily subcutaneously for 10 consecutive days. Dose levels were increased from 250 micrograms/m2 to 500, 750 and 1,000 micrograms/m2. Adverse effects were mainly fever, local irritation, lethargia, arthalgia. Three patients did not complete the 10-day cycle: one patient died due to progressive disease without toxic effects related to GM-CSF, one was withdrawn because of suspicion of pulmonary embolism (not confirmed), one patient had hypotension, not recurring after treatment with GM-CSF. Although the maximum tolerated dose was not reached, the trial was stopped at 1,000 micrograms/m2, considering the satisfactory response and the high white blood cell counts observed with lower dose levels. N-fold increases of leucocyte count ranged between 4.2 and 8.2 for the first dose level (250 micrograms/m2), 4 and 10.1 for 500 micrograms/m2, 8.5 and 12.3 for 750 micrograms/m2 and 5.6 and 8.3 for 1,000 micrograms/m2. Increases of granulocyte, neutrophil and eosinophil counts had a similar pattern with a weaker response at 1,000 micrograms/m2 (two patients who completed the cycle). In contrast, even for the first three levels, no dose response relationship was shown for increases of monocytes (between 2.8 and 12 n-fold whatever the dose), or lymphocytes (between 1.7 and 10.7 n-fold whatever the dose). Decreases of platelets (between 6 and 55%) were observed, followed by a rebound after stopping treatment. No modifications of erythrocyte count were observed. Subcutaneous GM-CSF was well-tolerated up to 1,000 micrograms/m2 during a 10-day course. Hematological effects were observed from the first dose level of 250 micrograms/m2.
Collapse
Affiliation(s)
- P Berthaud
- Service de médecine B, Institut Gustave-Roussy, Villejuif, France
| | | | | | | | | |
Collapse
|
30
|
Le Ceane A, Berthaud P, Brandely M, Toussaint C, Rixe O, Kayitalire L, Mezliai H, Spielmann M, Le Chevalier T, Tursz T. A broad spectrum phase II trial with continuous infusion (CI) of recombinant interleukin-2 (IL-2) in metastatic tumors. Eur J Cancer 1993. [DOI: 10.1016/0959-8049(93)90847-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
31
|
Berthaud P, Le Chevalier T, Ruffie P, Baldeyrou P, Arriagada R, Besson F, Tursz T. Phase I-II study of vinorelbine (Navelbine) plus cisplatin in advanced non-small cell lung cancer. Eur J Cancer 1992; 28A:1863-5. [PMID: 1327022 DOI: 10.1016/0959-8049(92)90023-u] [Citation(s) in RCA: 30] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
32 patients with advanced non-small cell lung cancer previously untreated by chemotherapy were included in a phase I-II study in order to determine the feasibility of the combination of vinorelbine and cisplatin, each administered at its optimal dose, i.e. 30 mg/m2 weekly and 120 mg/m2 every 4-6 weeks, respectively. There were 27 males and 5 females with a mean age of 55 years and a median performance status of 80%. 13 had locally advanced disease and 19 had distant metastases at the time of inclusion. Our study demonstrated the feasibility of this protocol. Dose intensities could be maximised by adapting vinorelbine doses rather than by postponing treatment in the event of neutropenia. Both response rate (33%) and overall survival of the population (median 11 months) justify further studies.
Collapse
Affiliation(s)
- P Berthaud
- Institut Gustave-Roussy, Villejuif, France
| | | | | | | | | | | | | |
Collapse
|
32
|
Tursz T, Dorval T, Berthaud P, Jouve M, Avril MF, Garcia-Giralt E, Le Chevalier T, Spielmann M, Sevin D, Palangie T. [Phase I trial of a recombinant human interleukin 2. Results in patients with disseminated solid tumors]. Presse Med 1991; 20:250-4. [PMID: 1826163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
A phase I trial of Roussel-Uclaf recombinant human interleukin 2 (IL 2) was performed on 31 cancer bearing patients of the Institut Gustave-Roussy, Villejuif, and the Institut Curie, Paris. This study allowed to define a schedule for administration of IL 2 in continuous infusion over 5 day cycles. This schedule is manageable in patients without major visceral failure. It is reproducibly feasible in conventional medical oncology units, without specialized intensive care facilities. Toxicities, although numerous, are acceptable for IL 2 doses below 24,000,000 IU/m2/day. There is a close relationship between secondary effect severity and IL 2 doses received. Main toxicities were: fever with chills, fatigue and general discomfort in 23 patients, nauseas and vomiting in 12, diarrhea in 10 and cutaneous rashes with erythema and dermal vascularitis in 13. One peculiar feature of this study was the minimal occurrence of manifestation related to leaky capillary syndrome prominant in other studies. Oliguria, functional renal failure and edema were observed in only 4 patients with functionally unique kidney. Five patients had severe anemia, 2 grade III thrombocytopenia, 1 grade IV hepatic cytolysis, 4 severe confusion episodes and 2 hypothyroidism with anti-thyroid microsome auto-antibodies. All these toxicities were reversible after withdrawal of IL 2 treatment. During this phase I trial, 3 therapeutic objective responses were observed, all 3 occurring in patients with metastatic melanoma treated with IL 2 doses equal to, or above 16,000,00 IU/m2/d. Recombinant IL 2 Roussel-Uclaf thus can be administered through a simple, manageable and efficient regimen.
Collapse
Affiliation(s)
- T Tursz
- Institut Gustave-Roussy, Villejuif
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Berthaud P, Schlumberger M, Comoy E, Avril MF, Le Chevalier T, Spielmann M, Tursz T. Hypothyroidism and goiter during interleukin-2 therapy. J Endocrinol Invest 1990; 13:689-90. [PMID: 2273212 DOI: 10.1007/bf03349600] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
34
|
|
35
|
Le Chevalier T, Zabbe C, Gouva S, Cerrina ML, Quoix E, Riviere A, Berthaud P, Prache C, Berille J. Phase II multicentre study of the nitrosourea fotemustine in inoperable squamous cell lung carcinoma. Eur J Cancer Clin Oncol 1989; 25:1651-2. [PMID: 2687005 DOI: 10.1016/0277-5379(89)90312-x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
36
|
Berthaud P, Le Chevalier T, Berille J, Herait P, Baldeyrou P, Tursz T, Arriagada R, Spielmann M, Hayat M. Phase II study of pirarubicin in advanced non-small cell lung cancer. Eur J Cancer Clin Oncol 1989; 25:1507-8. [PMID: 2556281 DOI: 10.1016/0277-5379(89)90113-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- P Berthaud
- Département de Médecine, Institut Gustave-Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Berthaud P, Le Chevalier T, Berille J, Herait P, Baldeyrou P, Tursz T, Arriagada R, Spielmann M, Hayat M. Phase II study of pirarubicin in advanced non-small cell lung cancer. Eur J Cancer Clin Oncol 1989; 25:1337-8. [PMID: 2553419 DOI: 10.1016/0277-5379(89)90082-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- P Berthaud
- Département de Médecine, Institut Gustave-Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | |
Collapse
|